July 8, 2021
Bottneuro was selected by the Venture Kick's jury of experts as one of the winners of the second stage of financial and entrepreneurial support. Their projects provide neuromodulation therapies for Alzheimer's disease, offer an efficient all-in-one solution for creating structured medical reports, and develop solutions with far greater flexibility in either stationary or mobile energy storage applications.
March 23, 2021
Bottneuro, together with Aegis Rider, Arkaïya, Celerato, and voltWALL win Venture Kick's first stage of financial and entrepreneurial support. Their projects develop a cutting edge augmented reality based safety system for motorcycles; produce a pioneer probiotic ingredient that promotes protection against a range of diseases and optimizes metabolism; provide neuromodulation therapies for Alzheimer's disease; offer an efficient all-in-one solution for creating structured reports, consisting of a comprehensive and intuitive software; and offer solutions with far greater flexibility in either stationary or mobile energy storage applications.
February 24, 2021
Spin-Offs To Watch 2021": Bottneuro AG selected as one of the 30 most promising spin-offs in the DACH region! Bottneuro entwickelt ultradünne Implantate für die elektrische Stimulation von Rückenmark und Gehirn, um die Belastung von Patienten mit Alzheimer und chronisch neuropathischen Schmerzen deutlich zu reduzieren. Das erst 2021 gegründete Unternehmen wird von Bekim Osmani, Alois C. Hopf und Tino Töpper geführt; seine Technik soll ab Mitte 2023 bereits bei ersten Patienten eingesetzt werden.
August 1, 2019
Within the Gebert Rüf Pilot Project, we are validated different stimulation protocols for non-neuronal cells using an in-vitro approach with NENI electrodes. Once successful, electrical stimulation protocols derived from in-vitro experiments will be translated to non-invasive transcranial electrical stimulations. By this, AD patients will benefit much earlier from our results and since the approach is non-invasive, it will become more accessible to a broader range of patients.